D.A. Davidson & CO. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 160.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 625 shares of the company’s stock after acquiring an additional 385 shares during the quarter. D.A. Davidson & CO.’s holdings in IDEXX Laboratories were worth $100,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. BlackRock Inc. grew its position in IDEXX Laboratories by 10.5% in the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares in the last quarter. Cipher Capital LP acquired a new stake in IDEXX Laboratories in the second quarter valued at approximately $2,284,000. Pitcairn Co. grew its position in IDEXX Laboratories by 21.8% in the second quarter. Pitcairn Co. now owns 6,977 shares of the company’s stock valued at $1,126,000 after acquiring an additional 1,249 shares in the last quarter. American Century Companies Inc. grew its position in IDEXX Laboratories by 131.7% in the second quarter. American Century Companies Inc. now owns 480,978 shares of the company’s stock valued at $77,639,000 after acquiring an additional 273,398 shares in the last quarter. Finally, Cutler Group LP grew its position in IDEXX Laboratories by 65.2% in the second quarter. Cutler Group LP now owns 3,800 shares of the company’s stock valued at $613,000 after acquiring an additional 1,500 shares in the last quarter. 87.64% of the stock is owned by institutional investors.
IDXX has been the subject of several recent research reports. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Stifel Nicolaus reissued a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Friday, July 14th. CL King raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Friday, July 28th. Canaccord Genuity reissued a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, August 22nd. Finally, Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $186.00 price target for the company in a research report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $174.00.
ILLEGAL ACTIVITY WARNING: “D.A. Davidson & CO. Purchases 385 Shares of IDEXX Laboratories, Inc. (IDXX)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2956896/d-a-davidson-co-purchases-385-shares-of-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company had revenue of $508.90 million during the quarter, compared to analyst estimates of $502.44 million. During the same period in the previous year, the company earned $0.74 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year.
In other IDEXX Laboratories news, Director Lawrence D. Kingsley purchased 2,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was bought at an average cost of $151.76 per share, for a total transaction of $303,520.00. Following the completion of the acquisition, the director now directly owns 3,344 shares in the company, valued at $507,485.44. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $150.79, for a total value of $1,960,270.00. Following the transaction, the chairman now owns 1,044,034 shares of the company’s stock, valued at $157,429,886.86. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 151,734 shares of company stock valued at $23,436,626. Corporate insiders own 2.77% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.